Sugi Predict

Sugi Predict / Compounds / SCHEMBL608700

SCHEMBL608700

SCHEMBL608700

COC(=O)c1c(Cl)cc(Cl)c(OC)c1[N+](=O)[O-]

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ GRIN2D O15399 1/20 0.48
▸ GRIN3B O60391 1/20 0.48
▸ GRIN1 Q05586 1/20 0.48
▸ GRIN2A Q12879 1/20 0.48
▸ GRIN2B Q13224 1/20 0.48
▸ GRIN2C Q14957 1/20 0.48
▸ GRIN3A Q8TCU5 1/20 0.48
▸ PKM P14618 1/20 0.42
▸ TSHR P16473 2/20 0.41
▸ COMT P21964 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ POLB P06746 3/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL611961 0.86 PKM (0.50) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL31470179 0.85 SMN1; SMN2 (0.49) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7902778 0.83 SMN1; SMN2 (0.49) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL31470133 0.83 SMN1; SMN2 (0.49) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8875531 0.80 SMN1; SMN2 (0.82) SMN1; SMN2PKMTSHRCOMTALDH1A1
SCHEMBL613006 0.80 SMN1; SMN2 (0.47) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11217561 0.79 SMN1; SMN2 (0.47) SMN1; SMN2PKMTSHRCOMTALDH1A1
SCHEMBL6906711 0.79 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1KDM4EGAAMEN1
SCHEMBL30954090 0.77 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1MEN1KMT2APOLB
SCHEMBL30954148 0.77 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059726-A1 NOVEL THERAPY Alterity Therapeutics Limited (AU) 2025-03-27 — — WO disclosed
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 — — EP disclosed
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 — — EP disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 — — US disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 — — US disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 — — US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 — — US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 — — US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 — — US disclosed
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 — — US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 — — US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 — — US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 — — US disclosed
US-8084459-B2 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract PRANA BIOTECHNOLOGY LTD (AU) 2011-12-27 — — US disclosed
US-8084459-B2 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract PRANA BIOTECHNOLOGY LTD (AU) 2011-12-27 — — US disclosed
EP-2379510-A1 QUINAZOLINONE COMPOUNDS Prana Biotechnology Ltd (AU) 2011-10-26 — — EP disclosed
WO-2010071944-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-07-01 — — WO disclosed
WO-2010071944-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-07-01 — — WO disclosed
US-20080119470-A1 Neurologically-Active Compounds XOMA TECHNOLOGY LTD. 2008-05-22 — — US disclosed
US-20080119470-A1 Neurologically-Active Compounds XOMA TECHNOLOGY LTD. 2008-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NDUFV2 SMN1; SMN2 354/4885GRIN2D 585/4885GRIN3B 245/4885
US-20080119470-A1 Neurologically-Active Compounds ACHE, PSEN1, PSEN2 SMN1; SMN2 11/4885GRIN2D 166/4885GRIN3B 74/4885
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 SMN1; SMN2 525/4885GRIN2D 667/4885GRIN3B 266/4885
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 SMN1; SMN2 525/4885GRIN2D 667/4885GRIN3B 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.